## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.1% below STRENGTH zone (3.0-6.0%); PEG 159.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. Have Insiders Sold Sarepta Therapeutics Shares Recently?**
- Source: Simply Wall Street | 20251220T160936 | Somewhat-Bearish | Relevance: 100%
- Sarepta Therapeutics' President & COO, Ian Estepan, recently sold US$294k worth of shares, representing 6.4% of his holding. While the sale occurred at around the current share price, signaling a minor caution, the company maintains significant insider ownership of 5.2%. However, the absence of insider buying over the past year, coupled with recent sales, suggests a degree of hesitation despite high insider ownership.

**2. Have Insiders Sold Sarepta Therapeutics Shares Recently?**
- Source: Simply Wall Street | 20251220T130834 | Neutral | Relevance: 100%
- An insider at Sarepta Therapeutics, Inc. (NASDAQ:SRPT) recently sold US$294k worth of shares, though this represented only a small portion of their total holdings. While significant insider ownership exists, there have been no insider share purchases in the past year, only sales. This article suggests caution due to the history of insider selling despite strong insider ownership.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Wedbush | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Wedbush | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 4 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)
- Renaissance Technolo: 2.5% (+324.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.7% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 159.2x requires aggressive growth execution.
3. High short interest (21.6%, 3.4 days to cover): squeeze risk or crowded bearish bet.
4. Long-term trend broken: trading 32.9% below SMA200.
5. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.2B |
| Beta | 0.53 |
| 52W Range | $10.42 - $129.84 |
| Short Interest | 21.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 7.6 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 2.7% to -2.1% (-4.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.1pp (needs >3.0% for momentum thesis). Below SMA200 (0.67x), long-term trend not supportive. RSI neutral at 52. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.07% (CS: 17) | Weak |
| RSI_14 | 52.1 | Neutral |
| MACD Histogram | -0.08 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.022x | Above |
| vs SMA200 | 0.671x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $21.23
- **Stop Loss:** $18.61 (12.3% risk)
- **Target:** $23.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 458
- **Position Value:** $9,723.34
- **Portfolio %:** 9.72%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*